The Institute

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

Retrieved on: 
Tuesday, March 19, 2024
College, PI3, Data science, Machine, Deep learning, Therapy, Harvard University, Audit trail, Membrane protein, School, Statistics, Biotechnology, ICR, Electrical engineering, Princeton University, 3D, Dartmouth College, Breast cancer, SAB, Applied science, Drug resistance, Royal, Machine learning, Computer science, Drug discovery, Associate, Royal Society, Intelligence, Research, AKT, Cancer, University, Cancer research, DARPA, Howard Hughes Medical Institute, Drug development, Principal, AstraZeneca, Entrepreneurship, The Institute, Biomarker, Columbia University, Faculty, Saint John's College, Stanford University, Chemical engineering, Medicine, Management

LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.

Key Points: 
  • LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.
  • This pioneering technology enables CHARM to target and develop treatments for previously hard-to-drug targets in cancer and other therapeutic areas.
  • Laksh Aithani, Co-Founder, Chief Executive Officer and Board Member of CHARM Therapeutics, said: “As CHARM advances its 3D deep learning platform in discovery it’s critical to maintain aligned oversight of our priorities and keep abreast of this emerging field.
  • Founding members of CHARM’s SAB:
    David Baker, Ph.D. is a Scientific Co-Founder at CHARM and Chair of the SAB.

REMADE CTO To Discuss “Reimagining Energy Use with Digital Technologies” at SXSW®

Retrieved on: 
Thursday, February 29, 2024
SXSW, Champaign–Urbana metropolitan area, CESMII, Manufacturing USA, REMADE, Digital, Advanced Materials, Government, Risk, Smart, University, The Institute, Associate, Austin Convention Center, Science, Workforce, Research, Partnership, Renewable energy

Since 2015, Dr. Azer has served as the Associate Director for Manufacturing Science at the Illinois Applied Research Institute at the University of Illinois at Urbana-Champaign.

Key Points: 
  • Since 2015, Dr. Azer has served as the Associate Director for Manufacturing Science at the Illinois Applied Research Institute at the University of Illinois at Urbana-Champaign.
  • The panel will also highlight how Manufacturing USA builds collaborative innovation ecosystems to advance these critical technologies.
  • Today, digital technologies are helping reimagine manufacturing processes and products to reduce energy use, decrease emissions, and eliminate waste, creating “circular economy” product flows; increasing energy efficiency through smart manufacturing; and employing digital capabilities in new ways to enhance sustainability.
  • REMADE enables early-stage applied research and development that will create jobs, dramatically reduce embodied energy and greenhouse gas emissions, and increase the supply and use of recycled materials.

International forum highlights the transformative power of lifestyle medicine to treat chronic disease and redefine health care

Retrieved on: 
Wednesday, February 28, 2024
Education, Death, Society, Non-communicable disease, CHES, American College, The Institute, Certification, WHO, IPH, Notifiable disease, International Board, Pharmacist, FACPM, Physician, Dentist, Weill Cornell Medicine, ACLM, CHWC, United Nations, Nursing, MPH, Knowledge, UN, LMGA, Human, Master of Science, United, CWP, Population health, Cancer, Public health, World Health Organization, Medicine, Pharmaceutical industry

ST. LOUIS, Feb. 28, 2024 /PRNewswire-PRWeb/ -- More than two dozen international experts in lifestyle medicine from 21 countries converged recently in Qatar at a forum to advocate for the growing medical specialty as an effective approach to treating noncommunicable chronic disease and transforming health worldwide.

Key Points: 
  • The Feb. 17 event, "Lifestyle Medicine - Redefining Healthcare to Promote Wellbeing," was organized by The Institute for Population Health (IPH) of Weill Cornell Medicine-Qatar, the Lifestyle Medicine Global Alliance (LMGA), and the International Board of Lifestyle Medicine (IBLM).
  • The forum was designed for physicians and other health professionals, including nurses, public health professionals, dentists, pharmacists, health care administrators, researchers and educators to develop the knowledge to discuss the growing field of lifestyle medicine and its opportunities, advancement and challenges.
  • Since certification in lifestyle medicine began in 2017, nearly 6,700 physicians and other health professionals have earned certification globally.
  • Ravinder Mamtani, MD, MSc, FACPM, FACOEM, DipABLM, vice dean for Population Health and Lifestyle Medicine, Weill Cornell Medicine – Qatar, and Sivaneswaran Poobalasingam, MD, DipIBLM, president of the Malaysian Society of Lifestyle Medicine, said the forum reinforced their belief that lifestyle medicine is "the way forward" for health care.

Mercy's Susan T. Peeler, M.D., and Patricia McMullen, WHNP, named Winners of inaugural Interprofessional Humanism in Healthcare Award

Retrieved on: 
Thursday, January 4, 2024
Woman, Health, Catholic higher education, BSN, Humanism, Collaboration, The Institute, MBA, Dean, University, Practitioner, FAAN, Family, DRS, Physician, JD, Catholic University of America, WHNP-BC, Hysteroscopy, Maryland School, WHNP, CNS, Patient, Mercy Hospital, Colposcopy, Gold, Partnership, GYN, AACN, Doctor of Philosophy, MD, FACOG, RN, Organization, Nursing

BALTIMORE, Jan. 4, 2024 /PRNewswire-PRWeb/ -- The Arnold P. Gold Foundation and the American Association of Colleges of Nursing (AACN) have announced the winners of the inaugural AACN-Gold Interprofessional Humanism in Healthcare Award, a new honor that celebrates and elevates the collaboration of physicians and nurses.Susan Todd Peeler, M.D., FACOG, MBA, and Patricia McMullen, PhD, JD, CNS, WHNP-BC, were recognized in December 2023 for their partnership in supporting comprehensive women's healthcare and disseminating best practices on women's health to clinicians across a wide range of disciplines.

Key Points: 
  • Mercy's Susan T. Peeler, M.D., and Patricia McMullen, WHNP, have been named recipients of the inaugural AACN-Gold Interprofessional Humanism in Healthcare Award, a new honor that celebrates and elevates the collaboration of physicians and nurses.
  • The Institute provides routine women's healthcare, as well as services for complex gynecological issues for women of all ages.
  • The new award will be centered each year on a theme, which this year is "Innovations in Interprofessional Collaboration that Drive Humanism in Healthcare."
  • Peeler and McMullen will be presented with the AACN-Gold Interprofessional Humanism in Healthcare Award at the 2024 Gold Humanism Summit in Atlanta, Georgia.

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

Retrieved on: 
Tuesday, December 19, 2023
Trauma, The Institute, Psilocybin, Lead, Psychiatrist, Mental health, PTSD, Sunstone, Post-traumatic stress disorder, Psychology, Safety, Patient, CMPS, Pharmaceutical industry

This is believed to be the first study reporting on the feasibility of psilocybin as a potential treatment for PTSD.

Key Points: 
  • This is believed to be the first study reporting on the feasibility of psilocybin as a potential treatment for PTSD.
  • The open-label study evaluated the safety and tolerability of COMP360 psilocybin treatment in patients with PTSD as a result of trauma experienced as adults.
  • 22 participants received a single 25mg dose of investigational COMP360 psilocybin treatment.
  • It’s encouraging to see these initial safety results for COMP360 psilocybin treatment in this patient population and we look forward to a more detailed analysis of the study next year.”

XCMG Commissions the World's First New Energy Loader Production Line

Retrieved on: 
Tuesday, December 26, 2023
Research, SHE, Education, XCMG, The Institute, Carbon, CO2, Renewable energy

XUZHOU, China, Dec. 26, 2023 /PRNewswire/ -- XCMG Machinery (SHE: 000425, "XCMG") has officially inaugurated the XCMG Loading Equipment Research Institute (the "Institute") and commissioned the world's first new energy loader production line in Xuzhou, China.

Key Points: 
  • XUZHOU, China, Dec. 26, 2023 /PRNewswire/ -- XCMG Machinery (SHE: 000425, "XCMG") has officially inaugurated the XCMG Loading Equipment Research Institute (the "Institute") and commissioned the world's first new energy loader production line in Xuzhou, China.
  • The new energy loader production line is designed especially for new energy models and adapts to rapid product upgrades and iterations, laying a solid foundation for the intelligent manufacturing of new energy equipment products.
  • In addition to producing emission-free new energy vehicles, the product line also utilizes clean energy throughout the manufacturing process to eliminate industrial emissions.
  • Back in 2010, XCMG pioneered the world's first LNG loader, that established its leading position in the new energy loader sector.

XCMG Commissions the World's First New Energy Loader Production Line

Retrieved on: 
Tuesday, December 26, 2023
Multimedia, Research, SHE, Education, XCMG, The Institute, Carbon, CO2, Renewable energy

XUZHOU, China, Dec. 26, 2023 /PRNewswire/ -- XCMG Machinery (SHE: 000425, "XCMG") has officially inaugurated the XCMG Loading Equipment Research Institute (the "Institute") and commissioned the world's first new energy loader production line in Xuzhou, China.

Key Points: 
  • XUZHOU, China, Dec. 26, 2023 /PRNewswire/ -- XCMG Machinery (SHE: 000425, "XCMG") has officially inaugurated the XCMG Loading Equipment Research Institute (the "Institute") and commissioned the world's first new energy loader production line in Xuzhou, China.
  • The new energy loader production line is designed especially for new energy models and adapts to rapid product upgrades and iterations, laying a solid foundation for the intelligent manufacturing of new energy equipment products.
  • In addition to producing emission-free new energy vehicles, the product line also utilizes clean energy throughout the manufacturing process to eliminate industrial emissions.
  • Back in 2010, XCMG pioneered the world's first LNG loader, that established its leading position in the new energy loader sector.

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NDA, Paclitaxel, Woman, Institute of Cancer Research, Research, Safety, Food, Avutometinib, Cancer, Letrozole, Disease, Verastem Oncology, Patient, Anastrozole, GOG, PFS, Consultant, RAMP, Breakthrough therapy, Part, FDA, NHS foundation trust, FRAME, ORR, The Institute, Ovarian cancer, FRCP, Doctor of Philosophy, Physician, Accelerated approval (FDA), Royal Marsden Hospital, Pharmaceutical industry, MBBS, Topotecan

“Patients and treating physicians have advocated for more research and development in support of LGSOC.

Key Points: 
  • “Patients and treating physicians have advocated for more research and development in support of LGSOC.
  • At Verastem Oncology, we are moving with urgency to offer a Phase 3 study specifically directed at this disease in an effort to address this need,” said Dan Paterson, President and Chief Executive Officer, Verastem Oncology.
  • RAMP 301 is a global trial with enrollment open in the U.S. and planned enrollment in Canada, the United Kingdom, Europe, Australia, and Korea.
  • Dr. Grisham and Dr. Banerjee are paid consultants for Verastem Oncology.

CCRM Fertility Releases First-of-its-kind Survey on Black Fertility

Retrieved on: 
Tuesday, November 7, 2023
Fertility, Education, Organization, Empowerment, Research, Reproductive medicine, Medicine, The Institute, Cooperman Barnabas Medical Center, Woman, Hunger, Patient, Infertility, Birth control, Rare-earth element, Black, Science

DENVER, Nov. 7, 2023 /PRNewswire/ -- CCRM Fertility, a global pioneer in fertility treatment, research, and science, today released results from their inaugural Black Fertility Matters survey* on the experiences of Black women and men related to fertility health. CCRM Fertility's Black Fertility Matters survey, a first-of-its-kind initiative, reached out to 1,000 Black men and women across the United States aged 24-54. It revealed several racial and cultural barriers that impede access to quality fertility care and treatment for the Black community, preventing many from achieving their family planning goals. Most notably, more than half (57%) of respondents believe Black individuals are less likely to seek fertility treatment, and 26% experienced racial/cultural bias when seeking fertility treatment.

Key Points: 
  • CCRM Fertility's Black Fertility Matters survey, a first-of-its-kind initiative, reached out to 1,000 Black men and women across the United States aged 24-54.
  • CCRM Fertility's Black Fertility Matters survey was conducted following the launch of the CCRM Fertility Black Fertility Matters Fund in May of 2023.
  • To learn more about CCRM Fertility and the Black Fertility Matters Fund, or to inquire about fertility treatment options, visit ccrmivf.com .
  • *Source: 2023 CCRM Fertility Black Fertility Matters Survey Via Pollfish.

ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Part Two, Patient, Incidence, Institute of Cancer Research, Doctor of Philosophy, Poster, CD8, Phase, SITC, Immunotherapy, University of London, NK, The Institute, Cancer research, CET, University, Safety, Society, Therapy, Pharmaceutical industry, Vaccine, Cancer

Marseille, France, November 3, 2023, 7 pm CET – ImCheck Therapeutics presented today updated data from its ongoing Phase I/IIa EVICTION-2 clinical trial at the Society for Immunotherapy of Cancer 38th annual meeting in San Diego, USA.

Key Points: 
  • Marseille, France, November 3, 2023, 7 pm CET – ImCheck Therapeutics presented today updated data from its ongoing Phase I/IIa EVICTION-2 clinical trial at the Society for Immunotherapy of Cancer 38th annual meeting in San Diego, USA.
  • “The data show a clear increase in γ9δ2 T cell counts as well as activation and mobilization of CD8 T cells and NK cells, indicating ICT01 in combination with low dose IL-2 can generate a broad immune response.
  • EVICTION-2 is a two-part, open-label, Phase I/IIa trial assessing the safety, tolerability, pharmacodynamics and anti-tumor effects of ICT01 in combination with low dose IL-2 in advanced-stage solid tumor patients.
  • Reported treatment-related adverse events were mainly mild to moderate and correlated with the profile of ICT01 and IL-2 monotherapy.